Table 8.
Liquid biopsy in neverous system cancers
| Cancer | Liquid biomarker | Origin | Tendency | Downstream target | Function | Reference |
|---|---|---|---|---|---|---|
| Glioblastoma | CTCs | Peripheral blood | up | Early diagnostic biomarker, Efficacy monitoring biomarker | 269 | |
| ctDNA mutation | CSF | up | Early diagnostic biomarker | 260 | ||
| ctDNA H3K27M mutation | CSF | up | Early diagnostic biomarker, Efficacy monitoring biomarker | 272 | ||
| ctDNA methylation | CSF | up | Early diagnostic biomarker | 268 | ||
| MCPH1 methylation | Serum | up | Early diagnostic biomarker, Efficacy monitoring biomarker | 274 | ||
| miR-320, miR-574-3p | Serum exosome | up | Early diagnostic biomarker | 276 | ||
| miRNA | CSF | up | Early diagnostic biomarker | 277 | ||
| PCNSL | MYD88, CARD11, CD79 mutation | CSF | up | Early diagnostic biomarker | 280 | |
| MYD88 | CSF | up | Early diagnostic biomarker | 284 | ||
| miR-200c, miR-141 | CSF exosome | down | ATP1B3, DYNC1H1, MATR3, NUCKS1, ZNF638, NUDT4, RCN2, GNPDA1, ZBTB38, DOLK | Early diagnostic biomarker, Efficacy monitoring biomarker | 289 | |
| SPP1, MARCKS, NPM1, VIM | CSF exosome | up | Early diagnostic biomarker | 291 | ||
| IL-10, sIL-2R | CSF | UP | Early diagnostic biomarker | 292 | ||
| IL-10 | CSF | up | Early diagnostic biomarker | 293 | ||
| Neopterin | CSF | UP | Early diagnostic biomarker | 295 |